Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorolanib + cadonilimab for previously untreated advanced renal cell carcinoma
ChiCTR2400086552Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jul 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vorolanib and cadonilimab in renal cell carcinoma (RCC) and kidney cancer, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Objective response rate. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
vorolanibcadonilimab
03
Conditions
renal cell carcinoma (RCC)kidney cancer
Beyond the preview
Go deeper on ChiCTR2400086552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086552.